Matt Gantz

Matthew Gantz joined BTG in February 2009. He is Executive Vice President, US, with responsibility for BTG's global interventional pulmonology business and administrative oversight for US business operations.

He is also a non-executive director of Swedish Orphan Biovitrum, a publically traded rare diseases company in Sweden, and a board member of PA Bio, the industry trade association for the life sciences sector in Pennsylvania.

Prior to BTG, Matthew was Founder and CEO of Acureon Pharmaceuticals, a specialty pharmaceutical company focused in the hospital areas of infectious diseases, transplant and ICU.

Prior to Acureon, he was the President and CEO of Hydrabiosciences Inc, a privately held biotechnology company developing novel, ion channel medicines in the pain and cardiovascular area.

From 2000 to 2003, Matthew was the VP Europe for Chiron’s Biopharmaceutical Division where he was directly responsible for $100+ million Infection Disease and Oncology business. From 1996 to 2000 he was the GM for PathoGenesis Europe before the company was acquired by Chiron.

Prior to Chiron/PathoGenesis, Matthew held a variety of US sales and marketing roles at Abbott Laboratories Diagnostics Division. Matthew served as an infantry officer in the US Marine Corps, earned his MBA from Harvard and his undergraduate degree from Princeton University.